• 1
    Fontana RJ, Lok ASF. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36: S5764.
  • 2
    Lotterer E, Hogel J, Gaus W, Fleig W, Bircher J. Quantitative liver function tests as surrogate markers for end-points in controlled clinical trials: a retrospective feasibility study. Hepatology 1997; 26: 6.
  • 3
    Reichen J. Assessment of hepatic function with xenobiotics. Semin Liver Dis 1995; 15: 3.
  • 4
    Tanaka E, Breimer DD. In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease. J Clin Pharm Ther 1997; 22: 23749.
  • 5
    Figg W, Dukes G, Lesesne H, et al. Comparison of quantitative methods to assess hepatic function: Pugh’s classification, indocyanine green, antipyrine, and dextromethorphan. Pharmacotherapy 1995; 15: 6.
  • 6
    Everson GT, Martucci MA, Shiffman ML, et al. Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt. Aliment Pharmacol Ther 2007; 26: 40110.
  • 7
    Hoefs JC, Wang F, Kanel G, Braunstein P. The liver-spleen scan as a quantitative liver function test: correlation with liver severity at peritoneoscopy. Hepatology 1995; 22: 111321.
  • 8
    Hoefs JC, Wang F, Kanel G. Functional measurement of the non-fibrotic hepatic mass in cirrhotic patient. Am J Gastroenterol 1997; 92: 20548.
  • 9
    Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 47292.
  • 10
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 4129.
  • 11
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 246774.
    Direct Link:
  • 12
    Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd edn. New York, NY: John Wiley and Sons, 2000.
  • 13
    SAS Institute, Inc., SAS/STAT® 9.1 User’s Guide, Cary, NC: SAS Institute, Inc., 2004.
  • 14
    Rosner B. Fundamentals of Biostatistics, 3rd edn. Belmont, CA: Duxbury Press, 1990.
  • 15
    Hoefs J, Chang K, Wang F, Kanel G, Morgan T, Braunstein P. The perfused Kupffer cell mass: correlation with histology and severity of CLD. Dig Dis Sci 1995; 40: 55260.
  • 16
    Hoefs JC, Wang F, Lilien D, Walker B, Kanel B. A novel, simple method of functional spleen volume calculation by liver-spleen scan. J Nucl Med 1999; 40: 174555.
  • 17
    Shrestha R, McKinley C, Showalter R, et al. Quantitative Liver Function Tests (QLFTs) define the functional severity of liver disease in early stage cirrhosis. Liver Transpl Surg 1997; 3: 16673.
    Direct Link:
  • 18
    Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 144957.
  • 19
    Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133: 4818.
  • 20
    Samonakis DN, Cholonngitas E, Thalheimer U, et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl 2007; 13: 130511.
  • 21
    Trotter JF, Osborne JC, Heller M, Christian U. Effect of hepatitis C infection on tacrolimus dose and blood levels in liver transplant recipients. Aliment Pharmacol Ther 2005; 22: 3744.
  • 22
    Wolffenbuttel L, Poli DD, Manfro RC, Goncalves LF. Cyclosporine pharmacokinetics in HCV+ patients. Clin Transplant 2004; 18: 65460.
  • 23
    Robertson SM, Scarsi KK, Postelnick MJ, Lynch P. Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review. Pharmacotherapy 2005; 25: 106872.
  • 24
    Kugelmas M, Osgood M, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejections. Liver Transpl 2003; 9: 115965.
  • 25
    Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16: 18594.